Your Best Stock

Bristol-Myers Squibb BMY

US equityMarket cap rank #122Drug Manufacturers - GeneralCancer Research
$60.90
−$0.26 (-0.42%)
Market open · Sep 24, 2:00 pm ET
After hours $61.34 +0.31%
Open$61.21
Prev close$61.15
Day range$60.60 – $61.57
Volume4.64M
Market cap$124.39B
P/E (TTM)13.4
Dividend yield4.12%

Earnings

Average move on report day±4.5%last 15 reports
Closed higher9 of 1560% of the time
Best reaction+11.4%
Worst reaction-8.5%

Stock move on the day after each report

-6.4%2023/Q3+0.1%2023/Q4-8.5%2024/Q1+11.4%2024/Q2+5.9%2024/Q3-3.8%2024/Q4+0.3%2025/Q1-5.8%2025/Q2+7.1%2025/Q3+3.3%2025/Q4+5.2%2026/Q1+2.8%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q329 Oct 2026Pre Market–––
2026/Q230 Jul 2026Pre Market±2.0%+2.79%Bigger than priced
2026/Q130 Apr 2026Pre Market±2.3%+5.21%Bigger than priced
2025/Q45 Feb 2026Pre Market±2.1%+3.30%Bigger than priced
2025/Q330 Oct 2025Pre Market±1.8%+7.09%Bigger than priced
2025/Q231 Jul 2025Pre Market±2.3%-5.81%Bigger than priced
2025/Q124 Apr 2025–±2.6%+0.33%Within range
2024/Q46 Feb 2025–±3.4%-3.84%Bigger than priced
2024/Q331 Oct 2024Pre Market±2.4%+5.91%Bigger than priced
2024/Q226 Jul 2024Pre Market±2.7%+11.44%Bigger than priced
2024/Q125 Apr 2024Pre Market±1.7%-8.51%Bigger than priced
2023/Q42 Feb 2024Pre Market±2.5%+0.08%Within range
2023/Q326 Oct 2023Pre Market±1.7%-6.43%Bigger than priced
2023/Q227 Jul 2023Pre Market±1.9%-4.23%Bigger than priced
2023/Q127 Apr 2023Pre Market±2.0%-0.60%Within range
2022/Q42 Feb 2023Pre Market±2.4%+2.16%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Eliquis$4.48B 34.5%
  • Opdivo$2.49B 19.2%
  • Other$1.49B 11.5%
  • Orencia$1.03B 8.0%
  • Yervoy$769.00M 5.9%
  • Reblozyl$735.00M 5.7%
  • Other Growth products$653.00M 5.0%
  • Breyanzi$484.00M 3.7%
  • Revlimid$425.00M 3.3%
  • Camzyos$416.00M 3.2%

Latest reported quarter: Q2, ended Jun 2026

Revenue$12.97B+5.7% YoY
Operating profit$4.03B+6.7% YoY
Net profit$3.32B+152.6% YoY
Diluted EPS$1.62+153.1% YoY
Free cash flow$3.09B-13.2% YoY
Operating cash flow$3.39B

Revenue, last 8 quarters

$11.9BSep '24$12.3BDec '24$11.2BMar '25$12.3BJun '25$12.2BSep '25$12.5BDec '25$11.5BMar '26$13.0BJun '26

Net profit, last 8 quarters

$1.2BSep '24$76.0MDec '24$2.5BMar '25$1.3BJun '25$2.2BSep '25$1.1BDec '25$2.7BMar '26$3.3BJun '26

Profitability & balance sheet

Gross margin70.2%
Operating margin28.1%
Net margin18.9%
Return on equity46.7%
Return on assets10.2%
Return on invested capital15.7%
Current ratio1.53
Liabilities / assets74.5%
Cash & investments$11.07B
Total debt$44.85B
Net cash (debt)-$33.78B
Free cash flow / sales23.3%
Scroll to Top